FDA Reclassifies BPC 157 & TB 500 What the Research Shows #Shorts YouTube Last week @fda sends out clarification on who can and cannot compound #glp1 like #tirzeaptide and #semaglutide and this week ProRx 503b shuts down GLP 1 compounding while @martymakary is photographed holding bootleg # PEPTIDES: THE 2026 FDA CRACKDOWN CONTROVERSYWhy this is MASSIVE SEO RIGHT NOW BPC 157 banned FDA Peptide Reclassification 2026: What Researchers Want Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Category 1 vs. Category 2. The FDA's peptide update, explained. Category 2 peptides are on the FDA's difficult to compound list, which effectively blocks licensed pharmacies from producing them. Category 1 means